Quantification of the anti-influenza drug zanamivir in plasma using high-throughput HILIC-MS/MS

• Published in: Bioanalysis Vol. 3; no. 2; p. 157
• Main Authors: Lindegardh, Niklas, Hanpithakpong, Warunee, Kamanikom, Benjamas, Farrar, Jeremy, Hien, Tran Tinh, Singhasivanon, Pratap, White, Nicholas J, Day, Nicholas P J
• Format: Journal Article
• Language: English
• Published: England 01.01.2011
• Subjects: Antiviral Agents - blood; Antiviral Agents - therapeutic use; Chromatography, Liquid - instrumentation; Chromatography, Liquid - methods; Humans; Influenza, Human - drug therapy; Plasma; Reference Standards; Tandem Mass Spectrometry - instrumentation; Tandem Mass Spectrometry - methods; Zanamivir - blood; Zanamivir - therapeutic use
• ISSN: 1757-6199
• DOI: 10.4155/bio.10.189

parenteral zanamivir is a promising drug for the treatment of severe influenza. However, quantification of this polar drug in biological matrices has traditionally been difficult and the methods developed have been relatively insensitive. a high-throughput bioanalytical method for the analysis of zanamivir in human plasma using SPE in the 96-well plate format and LC coupled to positive MS/MS has been developed and validated according to US FDA guidelines. The method uses 50 microl of plasma and covers a large working range from 1-50, 000 ng/ml with a LOD of 0.50 ng/ml. this new LC-MS/MS assay is more sensitive than previous methods despite using a small plasma volume sample. It is particularly suitable for clinical studies on both parenteral and inhaled zanamivir.